[May 17, 2013]

Research and Markets: Drug Evaluation Report: Sanofi's and Genzyme's Aubagio (Teriflunomide) (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/vc9wvm/aubagio_multiple) has announced the addition of the "Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering.

PharmaPoint Drug Evaluation report, Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT (News - Alert)). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient fature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Sanofi's and Genzyme's Aubagio (teriflunomide) is an oral immunomodulatory drug that was approved by the FDA in September 2012 for the treatment of RRMS, thus becoming the second oral MS drug to reach the market after Gilenya. Aubagio contains the active metabolite of leflunomide (Arava; Sanofi), a drug that has been used to treat RA since 1998. The chemical similarity to leflunomide will benefit the initial Aubagio uptake, given physicians' experience with leflunomide. GlobalData expects the drug to be approved and launched in Europe in Q1/Q2 2013.

Scope

- Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Aubagio including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Aubagio for the top ten countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Aubagio (teriflunomide)

9 Appendix

For more information visit http://www.researchandmarkets.com/research/vc9wvm/aubagio_multiple

[ Back To TMCnet.com's Homepage ]